Levobupivacaina Altan

Levobupivacaine, the active ingredient in Levobupivacaina Altan, is a local anesthetic presented as a solution for epidural, infiltration, intrathecal and peripheral use. It provides surgical anesthesia and analgesia for patients undergoing surgery, postoperative pain management, and labor analgesia.

GNH USA supplies Levobupivacaina Altan as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levobupivacaine is employed in regional anesthesia to manage pain associated with surgical and obstetric procedures.

Surgical anesthesia: provides intra‑operative anesthesia for a variety of surgeries. Post‑operative analgesia: extends pain relief during the recovery period after surgery. Labor analgesia: offers effective pain control during childbirth.

Adverse reactions may occur following administration of levobupivacaine.

Common Side Effects: - Hypotension - Bradycardia - Dizziness - Nausea - Metallic taste - Headache

Serious or Rare Side Effects: - Seizures - Cardiac arrhythmia - Respiratory depression - Prolonged motor block - Allergic reactions (e.g., rash, angioedema) - Systemic toxicity with CNS and cardiovascular manifestations

Levobupivacaina Altan should be used with careful clinical monitoring.

Dose individualization: dose should be determined by the prescribing clinician based on patient factors and procedure. Cardiovascular monitoring: observe heart rate and blood pressure during and after administration. CNS monitoring: watch for early signs of toxicity such as tinnitus, metallic taste or visual disturbances. Pregnancy considerations: use only when the expected benefit justifies potential risk to the fetus. Drug interactions: avoid concurrent use with other local anesthetics or agents that may increase cardiotoxicity. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Levobupivacaina Altan may interact with other medications, altering its safety profile.

Major Interactions (Avoid): - Concurrent use with other amide local anesthetics: increased risk of systemic toxicity. - Potent CYP3A4 inhibitors (e.g., ketoconazole): may raise plasma concentrations. - Beta‑adrenergic blockers: can exacerbate bradycardia. - Drugs that lower seizure threshold (e.g., tramadol): heightened seizure risk. - High‑dose epinephrine co‑administration: may affect absorption and cardiovascular response.

Moderate Interactions (Monitor Closely): - Calcium channel blockers: monitor cardiovascular status. - CNS depressants (e.g., benzodiazepines): enhanced sedation possible. - Diuretics: monitor electrolyte balance.